US FDA seeks feedback on including certain subsets of population in clinical trials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is preparing a report on ways to increase the participation of elderly people, children, racially and ethnically diverse communities and medically underserved populations in drug clinical trials1.